CAMP4 Therapeutics Corporation
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $241.0M
- Price
- $3.84
- % Change (Daily % change from the live per-ticker quote feed.)
- -3.03%
- Volume
- 148.5K
About
CAMP4 Therapeutics Corporation, a biotechnology firm, was established in 2015 by Richard A. Young and Leonard Zon. Based in Cambridge, Massachusetts, its core focus is the identification and development of new therapeutic solutions for patients.
Quick stats
Shares outstanding62.8M
Computed float28.8M
Float / shares46.0%
Cash runway (months)41.9
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001736730
Websitehttps://www.camp4tx.com
AI Summary
AI-generated1/27
minorbullishclinical trial
CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder
CAMP4 Therapeutics received UK MHRA authorization to add UK sites to its global Phase 1/2 clinical trial of CMP-002, its lead antisense oligonucleotide candidate for SYNGAP1-related disorder.
The clearance builds on July 2026 authorizations from Australia's TGA/HREC and Argentina's ANMAT, and the company remains on track to initiate the first-in-human study in Q4 2026; EU filings are still under review.
CMP-002 is positioned as a potential first-in-class disease-modifying therapy for a condition affecting over 10,000 people in the US with no approved disease-modifying treatments.
Red flags
- Clinical-stage company with no revenue; release's own risk language cites substantial and increasing losses and the need for substantial additional financing
- Trial initiation and EU regulatory clearances remain pending -- timing risk on the Q4 2026 start